TYK40: Difference between revisions
https://pedsanesthesia.net/wikiOLD032021>JustinHamrick No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
In the infant population, which of the following NMBA is an intermediate acting agent? | In the infant population, which of the following NMBA is an intermediate acting agent? | ||
| Line 10: | Line 9: | ||
D. Pancuronium | D. Pancuronium | ||
<div class="mw-customtoggle-TYK_Answer" style="text-align: right; color:#0000ff">Click for Answer</div> | |||
<div class="mw-collapsible mw-collapsed" id="mw-customcollapsible-TYK_Answer"> | |||
<div class="mw-collapsible- | |||
==Answer== | ==Answer== | ||
The answer is A. Pancuronium is a long acting agent (>50 mins) in any population. While in adults and children rocuronium and vecuronium are intermediate acting agents (20-50 mins), in the infant population these agents have a consistently prolonged duration of action (making them long acting agents in this population). This is due to a longer residence time and a lower site concentration needed for effect (increased sensitivity) in the infant. | The answer is A. Pancuronium is a long acting agent (>50 mins) in any population. While in adults and children rocuronium and vecuronium are intermediate acting agents (20-50 mins), in the infant population these agents have a consistently prolonged duration of action (making them long acting agents in this population). This is due to a longer residence time and a lower site concentration needed for effect (increased sensitivity) in the infant. | ||
==Notes== | ==Notes== | ||
<references /> | <references /> | ||
==Keywords== | ==Keywords== | ||
</div> | </div> | ||
---- | ---- | ||
---- | ---- | ||
Latest revision as of 22:24, 23 January 2022
In the infant population, which of the following NMBA is an intermediate acting agent?
A. Atracurium
B. Rocuronium
C. Vecuronium
D. Pancuronium
Click for Answer